Home › Companies › Nektar Therapeutics › 2025-2026
Compiled from SEC Form N-PX filings and Nektar Therapeutics’s Form 8-K, filed 2026-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore Nektar Therapeutics in the interactive database Compare manager voting policies
These tallies are Nektar Therapeutics’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Howard W. Robin | 13,164,879 | 4,975,288 | 286,175 | -- | 4,588,835 | Majority: yes |
| Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes. | 18,154,226 | 161,005 | 111,111 | -- | 4,588,835 | Majority: yes |
This meeting is also recorded here as 2026-06-05; both records come from the same filing, so the date should be checked against it.
Source: Nektar Therapeutics, Form 8-K, filed with the SEC on 2026-06-05 — read the filing on EDGAR.
Each item below shows how the 181 asset managers that disclosed a Nektar Therapeutics vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Nektar Therapeutics’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 7 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Nektar Therapeutics’s own tally for this item (“Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”): 18,154,226 for, 161,005 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 33,786,032 outstanding shares: 53.7% for, 0.5% against (54.2% of the company cast a for/against vote).
The 177 asset managers below cast 99.8% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,037,577 | 0 | 0 | 0 | For |
| BVF INC/IL | 2,559,595 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 1,991,046 | 0 | 0 | 0 | For |
| Vanguard | 1,460,497 | 0 | 0 | 0 | For |
| Invesco | 808,319 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 550,000 | 0 | 0 | 0 | For |
| BlackRock | 549,414 | 0 | 0 | 0 | For |
| Woodline Partners LP | 407,278 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 351,849 | 0 | 0 | 0 | For |
| Charles Schwab | 336,219 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 330,449 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 279,150 | 0 | 0 | 0 | For |
| Two Sigma | 274,347 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 257,418 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Prosight Management, LP | 233,115 | 0 | 0 | 0 | For |
| State Street | 229,909 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 225,040 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 196,900 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 193,335 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 181,182 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 166,438 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 165,178 | 0 | 0 | 0 | For |
| Citadel | 164,694 | 0 | 0 | 0 | For |
Showing the 25 largest of 177 asset managers. See all 177 in the interactive database.
Combines 2 wordings of this item as funds reported it.
58% fund support · no official result
The 41 asset managers below cast 58% of the shares they voted on this item FOR (3,321,502 for, 2,446,530 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 299,656 | 2,436,304 | 0 | 0 | Against |
| Vanguard | 1,252,287 | 2,367 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 165,939 | 499 | 0 | 0 | For |
| Principal | 90,281 | 0 | 0 | 0 | For |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,361 | 53 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 31,320 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 0 | 4,680 | 0 | 0 | Against |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 3 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Nektar Therapeutics’s own tally for this item (“Elect Director: Howard W. Robin”): 13,164,879 for, 4,975,288 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 33,786,032 outstanding shares: 39% for, 15% against (53.7% of the company cast a for/against vote).
The 38 asset managers below cast 53.0% of the shares they voted on this item FOR (3,036,968 for, 2,695,051 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 299,656 | 2,436,304 | 0 | 0 | Against |
| Vanguard | 1,252,287 | 2,368 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 499 | 165,939 | 0 | 0 | Against |
| Principal | 0 | 90,281 | 0 | 0 | Against |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,361 | 53 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
| ProShares | 3,159 | 0 | 0 | 0 | For |
| Victory Capital | 3,127 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.
99.9% fund support · no official result
The 38 asset managers below cast 99.9% of the shares they voted on this item FOR (5,730,768 for, 1,250 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,735,960 | 0 | 0 | 0 | For |
| Vanguard | 1,253,524 | 1,130 | 1 | 0 | For |
| Invesco | 353,993 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 246,634 | 0 | 0 | 0 | For |
| Lord Abbett | 234,845 | 0 | 0 | 0 | For |
| Charles Schwab | 168,104 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 166,438 | 0 | 0 | 0 | For |
| Principal | 90,281 | 0 | 0 | 0 | For |
| DWS | 90,000 | 0 | 0 | 0 | For |
| BlackRock | 83,578 | 0 | 0 | 0 | For |
| State Street | 73,402 | 12 | 0 | 0 | For |
| Russell Investments | 60,150 | 0 | 0 | 0 | For |
| MassMutual | 42,037 | 0 | 0 | 0 | For |
| Equitable | 26,743 | 0 | 0 | 0 | For |
| ALGER FUNDS | 19,035 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 17,092 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 10,431 | 0 | 0 | 0 | For |
| Morgan Stanley | 10,394 | 0 | 0 | 0 | For |
| MML Series Investment Fund II | 10,221 | 0 | 0 | 0 | For |
| Empower | 8,646 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,760 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 4,748 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,000 | 0 | 0 | 0 | For |
| ProShares | 3,159 | 0 | 0 | 0 | For |
| Victory Capital | 3,127 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.
99.1% Majority: yes · of votes cast
Nektar Therapeutics’s own tally for this item (“Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”): 18,154,226 for, 161,005 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 33,786,032 outstanding shares: 53.7% for, 0.5% against (54.2% of the company cast a for/against vote).
The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,255 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MANGROVE PARTNERS IM, LLC | 0 | 0 | 3,057 | 0 | Abstain |
| APG Asset Management US Inc. | 1,200 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 55 | 0 | 0 | 0 | For |
Ranked by the number of Nektar Therapeutics shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 33,786,032 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 20.83% |
| 2 | BVF INC/IL | 7.58% |
| 3 | Two Seas Capital LP | 5.89% |
| 4 | Vanguard | 4.32% |
| 5 | Invesco | 2.39% |
| 6 | GREAT POINT PARTNERS LLC | 1.63% |
| 7 | BlackRock | 1.63% |
| 8 | Woodline Partners LP | 1.21% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.04% |
| 10 | Charles Schwab | 1.00% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 12.74% | 13F |
| FMR LLC | 8.99% | DEF14A |
| BVF PARTNERS L P/IL | 7.08% | 13G |
| Entities affiliated with Two Seas Global (Master) Fund LP | 5.80% | DEF14A |
| Entities affiliated with BVF Inc. | 3.78% | DEF14A |
| Vanguard Group | 3.04% | 13F |
| Two Sigma | 2.75% | 13F |
| G1 Execution Services, LLC | 2.40% | 13G |
| BlackRock | 2.05% | 13F |
| Citadel Advisors | 1.97% | 13F |
Percentages above are of 33,786,032 shares outstanding, as reported by Nektar Therapeutics on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nektar Therapeutics’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Nektar Therapeutics's shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 181 asset managers reported how they voted in their SEC Form N-PX filings, covering 576 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — FOR was 99.1% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Nektar Therapeutics's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-05.
Nektar Therapeutics proxy season coverage: 2023-2024 · 2025-2026 (this page).